Condition: MF,PMF,PPV-MF,PET-MF · Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd
This trial adopts a multicenter, open-label, positive drug parallel control clinical trial design, planning to enroll approximately 75 MF participants. Eligible participants will be stratified and assigned in a 1:1:1 ratio to the low-dose flonoltinib maleate tablet group, high-dose flonoltinib maleate tablet group, or the ruxolitinib tablet group. Stratification factor include the Dynamic International Prognostic Scoring System (DIPSS) risk classification (intermediate-2 and high risk)
This description comes directly from the study's public registry record.
Liangkun Sun · 15885742617 · liangkunsun@zenitar.cn
Zheng Jiang · 19048075294 · zhengjiang@zenitar.cn
Always discuss trial participation with your own doctor first.
| West China Hospital Sichuan University | Chengdu, Sichuan, China | Recruiting |
| Hematology Hospital, Chinese Academy of Medical Sciences | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06457425